Contineum Therapeutics Inc
For the period ended Jun 30, 2024. Filed Aug 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 14, 2024
CTNM$9.52+8.1%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and par value data)
| June 30, 2024 | December 31, 2023 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $77,230 | $15,526 |
| Marketable securities | 141,423 | 109,664 |
| Prepaid expenses and other current assets | 1,667 | 2,516 |
| Total current assets | 220,320 | 127,706 |
| Property and equipment, net | 801 | 678 |
| Other long-term assets | 3 | 1,283 |
| Operating lease right-of-use assets | 231 | 719 |
| Total assets | $221,355 | $130,386 |
| Liabilities, convertible preferred stock and stockholders' equity (deficit) | ||
| Current liabilities: | ||
| Accounts payable | $734 | $635 |
| Accrued expenses | 2,521 | 4,385 |
| Current portion of operating lease liabilities | 484 | 464 |
| Total current liabilities | 3,739 | 5,484 |
| Other long-term liabilities | — | 110 |
| Operating lease liabilities, net of current portion | 113 | 108 |
| Total liabilities | 3,852 | 5,702 |
| Convertible preferred stock, $0.001 par value; no shares authorized, issued, or outstanding at June 30, 2024; authorized shares—16,940,594 at December 31, 2023; issued and outstanding shares—15,906,236 shares at December 31, 2023 | — | 192,620 |
| Stockholders' equity (deficit): | ||
| Class A common stock, $0.001 par value; authorized shares—200,000,000 and 39,630,511 at June 30, 2024 and December 31, 2023, respectively; issued and outstanding shares—18,994,104 and 2,349,554 at June 30, 2024 and December 31, 2023, respectively | 19 | 2 |
| Class B common stock, $0.001 par value; authorized shares—20,000,000 at June 30, 2024; issued and outstanding shares—6,729,172 at June 30, 2024; no shares authorized, issued, or outstanding at December 31, 2023 | 7 | — |
| Preferred stock, $0.001 par value; authorized shares—10,000,000 at June 30, 2024; no shares issued or outstanding at June 30, 2024; no shares authorized, issued, or outstanding at December 31, 2023 | — | — |
| Additional paid-in-capital | 310,174 | 7,098 |
| Accumulated deficit | (92,570) | (75,144) |
| Accumulated other comprehensive income (loss) | (127) | 108 |
| Total stockholders' equity (deficit) | 217,503 | (67,936) |
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) | $221,355 | $130,386 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.